Details

For years major corporations have conducted scientific research for commercial reasons. But do they now have too much power? Does the quest for profit compromise intellectual independence, and make scientists risk averse? Or does private investment enable the development of research programs that the state cannot afford to fund? Gill Samuels is Senior Director of Science Policy and Scientific Affairs, Europe, for Pfizer Global Research and Development. A trained scientist, she has worked on the European Biotechnology Patent Directive. Chair: Daniel Glaser, neuroscientist at UCL.